Sensei Biotherapeutics In... (SNSE)
0.44
0.01 (2.09%)
At close: Mar 04, 2025, 10:11 AM
No 1D chart data available
| Bid | 0.42 |
| Market Cap | 10.99M |
| Revenue (ttm) | 2.85M |
| Net Income (ttm) | -29.81M |
| EPS (ttm) | -1.23 |
| PE Ratio (ttm) | -0.36 |
| Forward PE | -0.49 |
| Analyst | Buy |
| Ask | 0.45 |
| Volume | 17,776 |
| Avg. Volume (20D) | 377,596 |
| Open | 0.44 |
| Previous Close | 0.43 |
| Day's Range | 0.42 - 0.45 |
| 52-Week Range | 0.38 - 1.94 |
| Beta | 0.15 |
About SNSE
Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response; and Tumor Microenvironment Activated Biologics, a platform designed to unleash the anti-tumor po...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 4, 2021
Employees 28
Stock Exchange NASDAQ
Ticker Symbol SNSE
Website https://www.senseibio.com
Analyst Forecast
According to 3 analyst ratings, the average rating for SNSE stock is "Buy." The 12-month stock price forecast is $4, which is an increase of 815.75% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
9 months ago
-14.67%
Sensei Biotherapeutics shares are trading lower af...
Unlock content with
Pro Subscription
11 months ago
+0%
Sensei Biotherapeutics shares are trading higher after the company announced the publication of a peer-reviewed research paper in Nature Communications the described the mechanism of action of SNS-101 selectively targeting the active form of VISTA within the tumor microenvironment.
